knowledge -WSS

knowledge

author：entertainment 2025-09-05 11:31:37 - browse：5

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Lilly’s obesity pill cuts 15% of weight at highest dose in mid

WSS

Research misconduct: Proposed new rules face resistance

Think you might have Covid

Supreme Court rules employers must be more accommodating of religious observance

Dewpoint Therapeutics lays off staff after losing partnerships

Parkinson’s finding may lead to tests and, someday, treatments

UnitedHealth wins $3.3 billion takeover of Amedisys

hotspot

knowledge

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Alkermes shareholders re

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Peter Hotez and the public health issue of online harassment

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Apple is now the first public company to be valued at $3 trillion

Why doctors need education on FDA device approval process

Alkermes shareholders re

Eli Lilly, Pfizer, and others want in on the online prescription market

entertainment

GOP inquiry over gain

Prior authorization will have to move faster under new Biden rule

Here's how to stay safe from wildfire smoke amid reduced air quality

AI generated plenty of interest at JPM but not a lot of trust

Why doctors need education on FDA device approval process

Brazil's Jair Bolsonaro is barred from running for office until 2030

hotspot

leisure time

explore

hotspot